HighTower Advisors LLC Acquires 1,227 Shares of Harrow, Inc. (NASDAQ:HROW)

HighTower Advisors LLC lifted its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 13.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,127 shares of the company’s stock after purchasing an additional 1,227 shares during the quarter. HighTower Advisors LLC’s holdings in Harrow were worth $340,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HROW. JPMorgan Chase & Co. grew its position in Harrow by 443.1% during the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after buying an additional 194,480 shares in the last quarter. Barclays PLC grew its holdings in shares of Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company’s stock worth $2,365,000 after purchasing an additional 39,506 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after purchasing an additional 166,602 shares in the last quarter. State Street Corp lifted its position in Harrow by 2.2% during the third quarter. State Street Corp now owns 730,973 shares of the company’s stock worth $32,865,000 after purchasing an additional 15,554 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Harrow during the third quarter worth about $1,469,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Down 6.1 %

HROW stock opened at $24.98 on Wednesday. The stock has a market capitalization of $889.66 million, a P/E ratio of -26.57 and a beta of 0.69. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The firm has a 50-day moving average price of $28.53 and a 200-day moving average price of $37.72. Harrow, Inc. has a 12 month low of $9.86 and a 12 month high of $59.23.

Harrow (NASDAQ:HROW) last issued its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The firm had revenue of $66.83 million for the quarter, compared to analyst estimates of $66.01 million. As a group, equities research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HROW. B. Riley cut their price target on shares of Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $57.00 target price on shares of Harrow in a report on Monday.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.